2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have

Question Title

* 2. How many patients with pediatric AD do you manage per week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting:

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with pediatric AD in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How confident do you now feel in treating pediatric patients with newly approved therapies?

Extremely confident

Reasonably confident

Not very confident

Not at all confident

Uncertain

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Ask about AD-related pruritus and its effect on quality-of-life for patient and family

Consider earlier biologic treatment for children ages 6 months to <6 years with moderate to severe AD

Consider oral or topical JAK inhibitors for adolescents ages ≥12 years with moderate to severe AD

Monitor JAK inhibitor study findings more closely for long-term safety evidence in AD

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 10. When will you consider using newly approved treatments in pediatric patients?

Immediately

After more data are available

Will not use

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications	Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications Strongly agree	Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications Agree	Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications Neutral	Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications Disagree	Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications Strongly disagree
Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD	Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly agree	Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Agree	Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Neutral	Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Disagree	Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly disagree

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Peter Lio, MD effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 13. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for pediatric atopic dermatitis:

2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have - Evaluation (ID: i846-1)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with pediatric AD do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting:

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with pediatric AD in your practice?

Question Title

* 5. How confident do you now feel in treating pediatric patients with newly approved therapies?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 10. When will you consider using newly approved treatments in pediatric patients?

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Peter Lio, MD effectively:

Question Title

* 13. The content presented:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for pediatric atopic dermatitis:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with pediatric AD do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting:

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with pediatric AD in your practice?

Question Title

* 5. How confident do you now feel in treating pediatric patients with newly approved therapies?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 10. When will you consider using newly approved treatments in pediatric patients?

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now better able to:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating. Peter Lio, MD effectively:

Question Title

* 13. The content presented:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for pediatric atopic dermatitis:

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

* 12. Please rate your level of agreement by checking the appropriate rating.

Peter Lio, MD effectively: